Investigating changes to regulatory frameworks to enable cannabinoid products to be more easily accessed for therapeutic use.
The legislative landscape for medicinal cannabis in Australia has recently undergone a number of landmark changes. These include: revised scheduling classification of cannabis, federal licensing for cultivation and manufacturing, and approval for warehousing of imported product. While these changes have aimed to improve the accessibility of medicinal cannabis to patients, there are still a number of regulatory barriers hindering patient access. One problem is that the majority of cannabinoids designed for human therapeutic use – many of which are non-psychoactive – still reside within Schedule 8 of the Therapeutic Goods Administration’s classification scheme as very tightly controlled drugs.
We are investigating potential changes to this regulatory framework that would ‘down schedule’ some cannabinoid products to allow them to be more easily accessed for therapeutic use. The outcome of this work will be improved access to cannabinoids for research purposes and ultimately, for patients.
Project commenced – February 2018
Investigation into regulatory reform
The Lambert Initiative
Please contact Rhys Cohen for further information: